financetom
Business
financetom
/
Business
/
Salesforce Set to Exceed Q1 Estimates as Partners Report Healthy Deal Activity, BofA Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Salesforce Set to Exceed Q1 Estimates as Partners Report Healthy Deal Activity, BofA Says
May 15, 2024 9:47 AM

12:29 PM EDT, 05/15/2024 (MT Newswires) -- Salesforce ( CRM ) is expected to beat estimates for Q1 as feedback from its partners suggested that deal activity remained healthy, BofA Securities said in a note Wednesday.

The firm said it expects Salesforce ( CRM ) to report a 1 percentage point upside to its current remaining performance obligation, or cRPO, growth estimate of 12% and "some upside" to its earnings estimate of $2.37 per share for Q1. The company is scheduled to report its Q1 financial results on May 29.

The company's solid pipeline builds confidence in potential growth and supports cRPO growth outlook for Q2, BofA added.

"We expect management to flow through Q1 upside to the outlook for [fiscal year] 2025 subscription growth and margin of above 10% [constant currency] and 32.5%," according to the note.

The firm said the company was meeting its partners' expectations overall with a higher mix indicating better than expected results. Strong performance was noted in industry clouds, data cloud pilot deals and marketing cloud, according to the note.

"As the leader in the large customer relationship management industry, we believe the company can gain share and outpace industry growth," the firm said, quoting research and consultancy firm Gartner.

BofA said subscription reacceleration driven by contributions from the data cloud business is a potential catalyst for company shares rerating higher, as they are currently valued relatively low compared to the expected free cash flow growth.

BofA maintained its buy rating on the company's stock and kept the price objective at $360.

The company's shares were up 2.5% in recent trading.

Price: 283.79, Change: +6.99, Percent Change: +2.52

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Tegna Chief Operating Officer of Media Operations to Depart in 2025
Tegna Chief Operating Officer of Media Operations to Depart in 2025
Sep 22, 2024
10:17 AM EDT, 09/18/2024 (MT Newswires) -- Tegna ( TGNA ) said Wednesday that Chief Operating Officer of Media Operations Lynn Beall will leave the company in the middle of 2025. Beall joined the company in 1988 and has served as COO since 2017, the company said. Price: 15.00, Change: +0.16, Percent Change: +1.11 ...
BigCommerce, Ubique Digital Collaborate to Launch Travel Operations Solution
BigCommerce, Ubique Digital Collaborate to Launch Travel Operations Solution
Sep 22, 2024
10:18 AM EDT, 09/18/2024 (MT Newswires) -- BigCommerce ( BIGC ) said Wednesday it is collaborating with digital transformation agency Ubique Digital to launch BigTravel, a solution aimed at streamlining travel operations and improving overall customer experience. Financial details weren't disclosed. BigTravel is expected to simplify travel bookings, boost efficiency with real-time data, and personalize traveler experiences with mobile-optimized storefronts,...
Workday's GenAI, Partner Strength Propel Growth Amid Investor Concerns, RBC Says
Workday's GenAI, Partner Strength Propel Growth Amid Investor Concerns, RBC Says
Sep 22, 2024
10:54 AM EDT, 09/18/2024 (MT Newswires) -- Workday's (WDAY) medium-term growth is driven by artificial intelligence, partner enablement, full-suite deals and international expansion, RBC Capital Markets said in a note Wednesday. Despite macroeconomic challenges, about one-third of new customers in the trailing twelve months have adopted the full suite of products, with partners sourcing 9% of the new annual contract...
Organon to Buy Roivant's Dermatology Unit For Up to $1.2 Billion
Organon to Buy Roivant's Dermatology Unit For Up to $1.2 Billion
Sep 22, 2024
10:42 AM EDT, 09/18/2024 (MT Newswires) -- Organon (OGN) on Wednesday agreed to acquire Roivant Sciences' ( ROIV ) immuno-dermatology subsidiary, Dermavant, in a deal worth up to $1.2 billion. The healthcare company will pay $175 million upfront and up to $950 million for the achievement of certain commercial milestones. It will also pay $75 million upon the US Food...
Copyright 2023-2026 - www.financetom.com All Rights Reserved